Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Xeris Biopharma Holdings, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
09/27/2023 |
8-K
| Quarterly results |
08/09/2023 |
4
| Edick Paul R (See Remarks) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Bought 10,000 shares
@ $2.3794, valued at
$23.8k
|
|
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
06/28/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
06/07/2023 |
4
| BORMANN-KENNEDY BARBARA-JEAN ANNE (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
4
| Kong Garheng (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
4
| JOHNSON JOHN (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
4
| HALKUFF DAWN (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
4
| PERSKY MARLA (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
4
| Schmid John P. (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
4
| SHERMAN JEFFREY W (Director) has filed a Form 4 on Xeris Biopharma Holdings, Inc.
Txns:
| Granted 42,500 shares
@ $0 |
|
06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/09/2023 |
8-K
| Quarterly results |
04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
03/29/2023 |
8-K
| Quarterly results |
03/17/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
03/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/08/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 4.4% stake in Xeris Biopharma Holdings, Inc. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/10/2023 |
SC 13G
| BlackRock Inc. reports a 6.3% stake in XERIX BIOPHARMA HOLDINGS INC |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|